When it comes to treating chronic health conditions like high blood pressure, high cholesterol, blood clots, and type II diabetes, there are many different medications out on the market. For the treatment of type II diabetes, some of these medications may work better than others, but they also have downfalls to their use as well.
A study conducted involving nearly 500,000 patients with type II diabetes shows that there are pros and cons to nearly every medication used to treat the disease.
A British research study conducted followed 470,000 patients between 2007 and 2015 and looked at patient outcomes.
The intention of the study was to root out the differences among a variety of diabetes drugs. Researchers took into account possibly complicating factors such as age, sex, smoking, and poverty as well as how long each patient had been diagnosed with the condition.
The researchers’ focus was on the five major outcomes considered in patients with type II diabetes: blindness, amputation, severe kidney failure, and high and/or low blood sugar.
The outcome of the research showed that a class of drugs called glitazones (Avandia, Actos) when combined with the standard treatment drug Metformin, led to a higher risk of kidney failure than treatment with Metformin alone.
They found the same result when tracking outcomes of Metformin combined with another class of meds called gliptins. Gliptins include Juvia, Onglyza, and others.
The upside to these combinations is that patients who took a combination of either a gliptin or a glitazone along with Metformin had a lower incidence of high blood sugar than Metformin alone.
The study did not, however, establish a direct cause-and-effect relationship between the various drugs and these outcomes.
If you believe that you have suffered an injury or an adverse health event due to taking the prescribed drug Onglyza, you may be entitled to compensation. Contact the law offices of John Foy & Associates. The “Strong Arm” attorneys will work to get you compensation. Contact us today.